Clinical trials: Disease Prevention
Opioid Use Disorder, Relapse
Clinical Outcomes Following Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention: A Long-term Follow-up Study
This is a prospective, observational, longitudinal study to assess clinical outcomes in the 12-months following participants' exit from protocol SBM-OWP-03, Delivering Transcutaneous Auricular Neurostimulation to Improve Relapse…
- Trial name
- RESTOREb (NCT05591703)
- Testing
- Clinical Outcomes and Questionnaires
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Spark Biomedical, Inc.
Venous Thromboembolism, Cancer
Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy
The primary objective was to compare the efficacy of once daily subcutaneous injections of Semuloparin sodium (AVE5026) with placebo in the prevention of venous thromboembolism [VTE] in cancer patients at high risk for VTE and…
- Trial name
- SAVE-ONCO (NCT00694382)
- Testing
- Semuloparin sodium
- Where
- 411 sites in United States, Argentina and 47 more
- Volunteers
- 3,212 people
- Sponsor
- Sanofi
Colitis, Ulcerative, Recurrence
Once Daily (OD) Versus Three Times Daily (TID) Dosing With Mesalazine Granules for Prevention of Recurrence of Ulcerative Colitis (UC)
This study intends to study the efficacy and tolerability of once daily 3.0 g mesalazine granules vs. once daily 1.5 g mesalazine granules vs.
- Trial name
- NCT00746447
- Testing
- mesalamine granules
- Where
- Germany
- Volunteers
- 648 people
- Sponsor
- Dr. Falk Pharma GmbH
Congenital Bleeding Disorder, Haemophilia A
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
This trial is conducted in Asia, Europe and North America. The purpose of the trial is to evaluate the safety and efficacy of turoctocog alfa in prevention and treatment of bleeds in previously untreated children with haemophilia…
- Trial name
- guardian™4 (NCT01493778)
- Testing
- turoctocog alfa
- Where
- 69 sites in United States, Algeria and 16 more
- Volunteers
- 60 people
- Sponsor
- Novo Nordisk A/S
Marburg Hemorrhagic Fever
Safety Study of Single Administration Post-exposure Prophylaxis Treatment for Marburg Virus
The purpose of this study is to characterize the safety and pharmacology of single administrations of AVI-6003, a post-exposure prophylaxis candidate treatment for Marburg virus.
- Trial name
- NCT01353040
- Testing
- AVI-6003
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sarepta Therapeutics, Inc.
Peptic Ulcer Hemorrhage
IIaprazole for the Treatment and Prevention of Peptic Ulcer Bleeding in Chinese Patients
The purpose of this study is to compare the efficacy and safety of ilaprazole and omeprazole in the treatment and prevention of peptic ulcer bleeding.
- Trial name
- NCT03362268
- Testing
- Ilaprazole, omeprazole
- Volunteers
- 180 people
- Sponsor
- Livzon Pharmaceutical Group Inc.
COVID-19
AZD1222 Vaccine for the Prevention of COVID-19
The purpose of this study is to evaluate safety and immunogenicity of AZD1222 for COVID-19 prevention in the Russian Federation
- Trial name
- NCT04540393
- Testing
- AZD1222
- Where
- 4 sites in Russia
- Volunteers
- healthy volunteers welcome
- Sponsor
- AstraZeneca
HIV Infections, Cytopenias
A Randomized, Controlled, Multicenter Trial of Filgrastim (Recombinant-Methionyl Human Granulocyte Colony Stimulating Factor; G-CSF) for the Prevention of Grade 4 Neutropenia in Patients With HIV Infection.
To determine, in HIV-infected patients, the efficacy of filgrastim ( recombinant-methionyl human granulocyte-colony stimulating factor; G-CSF ) in preventing grade 4 neutropenia, i.e., absolute neutrophil count (ANC) < 500…
- Trial name
- NCT00002126
- Testing
- Filgrastim
- Where
- 22 sites in United States, Canada
- Volunteers
- 250 people
- Sponsor
- Amgen
Thrombosis
A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation
To investigate the safety and pharmacokinetics of apixaban in children with congenital or acquired heart disease who have a need for anticoagulation.
- Trial name
- NCT02981472
- Testing
- Apixaban, Vitamin K Antagonist (VKA), Low Molecular Weight Heparin (LMWH)
- Where
- 46 sites in United States, Argentina and 12 more
- Volunteers
- 192 people
- Sponsor
- Bristol-Myers Squibb
Atrial Fibrillation, Postoperative
Amiodarone-Infused CardiaMend Patches for the Prevention of New-Onset POAF in Cardiac Surgery Subjects
The goal of this clinical trial is to is to test the safety of a new way to deliver a commonly used drug (amiodarone) used in heart surgery by placing a patch containing the drug directly on the heart instead of in an IV (vein).
- Trial name
- AMIOMEND (NCT06730828)
- Testing
- The intervention includes Amiodarone-Infused CardiaMend patches (70mg, 150mg and 300mg)
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Helios Cardio Inc.
Migraine, Episodic Migraine
Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention
The purpose of this study is to further evaluate the long-term safety and tolerability of daily dosing of rimegepant for the prevention of episodic migraine.
- Conditions
- Migraine, Episodic Migraine, Phonophobia, Photophobia
- Trial name
- NCT05207865
- Testing
- Rimegepant
- Where
- 19 sites in United States
- Volunteers
- 441 people
- Sponsor
- Pfizer
Yellow Fever
Trial of Yellow Fever Inactivated Vaccine
The Phase 1 trial is a single-center, randomized, double blind, placebo-controlled, dose-ranging out-patient study designed to provide the first clinical data on the safety, tolerability and immunogenicity of XRX-001 inactivated…
- Trial name
- NCT00995865
- Testing
- XRX-001 Inactivated yellow fever vaccine
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
Breast Cancer, Neutropenia
Study to Compare the Efficacy and Safety of F-627 and GRAN®
A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Trial to Compare the Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F-627) and Recombinant Human Granulocyte…
- Trial name
- NCT04174599
- Testing
- F-627, GRAN®
- Where
- China
- Volunteers
- 242 people
- Sponsor
- EVIVE Biotechnology
Episodic Migraine
Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine
The purpose of this study is to evaluate the safety and tolerability of atogepant 60 mg once a day for the prevention of migraine in participants with episodic migraine.
- Trial name
- NCT03939312
- Testing
- Atogepant
- Where
- 113 sites in United States
- Volunteers
- 685 people
- Sponsor
- Allergan
Prostate Cancer
To Evaluate the Effect of MCS® in Prostate Cancer Prevention
To evaluate the effect of MCS® compared with placebo in reducing the risk of biopsy-detectable prostate cancer in high-risk subjects after 104 weeks (24 months) of treatment.
- Trial name
- MCS-8 (NCT02042807)
- Testing
- MCS®
- Where
- Taiwan
- Volunteers
- 702 people
- Sponsor
- Health Ever Bio-Tech Co., Ltd.
Neoplasms, Prostate
"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk
This 4-year study will compare how safe and effective an oral investigational medicine is (compared to placebo) in preventing the development of prostate cancer in men that are defined by the study entrance criteria as being at…
- Trial name
- REDUCE (NCT00056407)
- Testing
- Dutasteride
- Where
- 932 sites in United States, Argentina and 40 more
- Volunteers
- 8,231 people
- Sponsor
- GlaxoSmithKline
Neutropenia
Bioavailability Study of Lozanoc™ 65 mg Itraconazole Capsules in Patients Requiring Prophylaxis
This open-labelled, single arm study is a follow-on from Study MPG010 to compare the relative bioavailability of Lozanoc 65 mg Capsules against Lozanoc 50 mg Capsules and Sporanox 100 mg Capsules in patients requiring…
- Trial name
- NCT02755857
- Testing
- Lozanoc
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- Mayne Pharma International Pty Ltd
Depressive Disorder, Major Depression
A Study of SR58611A in the Prevention of Depression Relapse in Patients With Major Depressive Disorder
The purpose of the study is to assess whether treatment with SR58611A can prevent relapse of depressive symptoms in patients with major depressive disorder.
- Trial name
- CALYPSO (NCT00345098)
- Testing
- SR58611A
- Where
- 13 sites in Argentina, Bulgaria and 11 more
- Volunteers
- 704 people
- Sponsor
- Sanofi
Exposure to Hepatitis B Virus
Safety and Efficacy Study of Adjuvanted Prophylactic Hepatitis B Vaccine
There is a need for more effective and better-tolerated hepatitis B vaccines for low responder high-risk populations including patients with renal impairment and/or diabetes mellitus and those aged over 40 years.
- Trial name
- NCT01951677
- Testing
- HBsAg, PreS HBsAg, Advax-1(TM)
- Where
- Australia
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Vaxine Pty Ltd
Candidiasis, Oral, HIV Infections
A Study of Nystatin in the Prevention of Fungal Infections of the Mouth in Patients With AIDS or AIDS-Related Syndromes
To determine a safe, effective, and convenient dosing schedule for nystatin pastilles in the prophylaxis of oral candidiasis in patients with AIDS or AIDS related syndromes (group III or IV, CDC classification)
- Trial name
- NCT00002293
- Testing
- Nystatin
- Where
- 2 sites in United States
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.